Last updated on July 2019

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)


Brief description of study

To evaluate efficacy, safety and pharmacokinetic profile of asciminib 40mg+imatinib or asciminib 60mg+imatinib versus continued imatinib and versus nilotinib in pre-treated patients with Chronic Myeloid Leukemia in chronic phase (CML-CP)

Clinical Study Identifier: NCT03578367

Find a site near you

Start Over

Novartis Investigative Site

Seoul, Korea, Republic of
  Connect »

Novartis Investigative Site

Moscow, Russian Federation
  Connect »

Novartis Investigative Site

Saint Petersburg, Russian Federation
  Connect »

Novartis Investigative Site

Las Palmas de Gran Canaria, Spain
  Connect »

University of Chicago

Chicago, IL United States
  Connect »